ArticleChemotherapy research and practice2016

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India.

Govind Babu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.